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Background: GTP cyclohydrolase I (GCH1) mutations are the commonest cause of Dopa-responsive
dystonia (DRD). Clinical phenotypes can be broad, even within a single family.
Methods: We present clinical, genetic and functional imaging data on a British kindred in which affected
subjects display phenotypes ranging from DRD to Parkinson's disease (PD). Twelve family members were
studied. Clinical examination, dopamine transporter (DAT) imaging, and molecular genetic analysis of
GCH1 and the commonest known familial PD-related genes were performed.
Results: We have identiﬁed a novel missense variant, c.5A > G, p.(Glu2Gly), within the GCH1 gene in
affected family members displaying a range of phenotypes.
Two affected subjects carrying this variant had abnormal DAT imaging. These two with abnormal DAT
imaging had a PD phenotype, while the remaining three subjects with the novel GCH1 variant had
normal DAT imaging and a DRD phenotype.
Conclusions: We propose that this GCH1 variant is pathogenic in this family and these ﬁndings suggest
that similar mechanisms involving abnormal GTP cyclohydolase I may underlie both PD and DRD. GCH1
genetic testing should be considered in patients with PD and a family history of DRD.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dopa-responsive dystonia (DRD) is an autosomal dominant
dystonia, now classiﬁed as DYT5, with an estimated incidence of
between 0.5 and 1 per million [1]. DRD typically manifests as lower
limb dystonia in childhood, although the spectrum of symptoms
can be broad, even within the same family. Patients typically have
an excellent and sustained response to low dose levodopa. Women
are more commonly affected with a lower penetrance of mutations
in men [2,3].y, Sandwell and West Bir-
ham B18 7QH, UK. Tel.: þ44
ll).
ript.
Ltd. This is an open access article uMutations in the GTP cyclohydrolase I gene (GCH1) are the most
common cause of DRD. GCH1 is located on chromosome 14
(14q22.1-q22.2) and encodes the 32-kDa guanosine 50-triphos-
phate cyclohydrolase 1 (GTPCH1) protein. GCH1 contains six exons,
and more than 200 different mutations have been identiﬁed [1,2].
Single positron emission computerized tomography (SPECT)
Dopamine Transporter (DAT) imaging is a demonstration of in vivo
striatal dopamine activity. The DAT ligands for SPECT, including
[123I]FP-CIT (DaTSCAN) have all shown signiﬁcantly reduced striatal
uptake in PD [4], whilst uptake has usually been normal in DRD [5].
We have studied a family with an inherited movement disorder,
with phenotypes ranging from DRD to slowly progressive PD. We
report results from clinical, genetic and imaging studies of this
kindred.
2. Methods
Twelve members of the kindred were studied. A diagnosis of PD was made ac-
cording to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank clinicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Mental State Examination) were performed on each subject. Olfactory function was
assessed by use of the University of Pennsylvania Smell Identiﬁcation Test (UPSIT-
40) (Sensonics, Haddon Heights, NJ) and data compared to normative values. Seven
subjects (II:1-II:5, III:1 and III:11) underwent dopamine transporter SPECT scanning
(DaTSCAN, Amersham Health) and images reviewed by ER, who was blinded to
demographic and clinical data.
Molecular genetic screening of the six affected family members was performed
by polymerase chain reaction (PCR) and sequencing of the entire coding sequence,
and intron-exon boundaries, of the genes SNCA, Parkin, DJ-1, PINK1, LRRK2 and GCHI,
using primers and PCR conditions available on request. Multiple ligation-dependent
probe ampliﬁcation (MLPA) was used to detect the presence or absence of copy
number variation, using MLPA kits P051 and P052 (MRC Holland), details available
on request. Subsequently, six unaffected family members (II:2 and III:4,5,7,9,13) and
150 UK control DNA samples from the PD GEN DNA databank were screened for the
novel GCH1 variant.
All subjects gave informed written consent to take part in the study. The study
had appropriate ethical approval from South Birmingham LREC and Sandwell and
West Birmingham LREC.3. Results
Twelve individuals in the pedigree (Fig. 1, those annoted with an
age) were examined in detail. We noted features consistent with
slowly progressive PD in individuals II:1 and II:4 (Supplementary
video), with additonal levodopa-induced dyskinesias and dementia
in subject II:1. Disease onset was at 58 and 50 years in II:1 and II:4
respectively. Subject II:3 had an isolated rest tremor (asymmetrical,
right upper limb), with an older age of onset of 75 years, had not
progressed over six years and did not meet diagnostic criteria for
PD. Subjects II:5, III:1 and III:11 had features consistent with DRD,
with median age of disease onset 17 years and median disease
duration of 22 years. The remaining members of the family were
unaffected. All the studied subjects are Caucasian and clinical de-
tails of affected individuals are summarized in Table 1 (more clin-
ical details in Supplementary data).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2015.01.004.
The ﬁndings from DaTSCAN images on six affected subjects (II:1,
II:3-II:5, III:1 and III:11) and one unaffected subject (II:2) are
summarized in Table 1 (Supplementary data). Subjects II:3 and II:4Fig. 1. Pedigree of study family. Numbers refer to the age (in years) at clinicahad a second DaTSCAN performed 18 months after the ﬁrst scan
due to atypical disease progression (ie only very slowly progressing
which would be unexpected in idiopathic PD).
No novel or previously documented mutations were identiﬁed
in the coding sequences of SNCA, Parkin, PINK1, DJ-1 and LRRK2.
However, a novel heterozygous substitution was identiﬁed in the
ﬁrst exon of GCH1 affecting the ﬁfth nucleotide of the open reading
frame (c.5A > G) (Supplementary data). This change is predicted to
replace a glutamic acid residue with glycine (p.(Glu2Gly)). This
mutation (GenBank accession NM_000161.2, NP_000152.1.) is not
listed as a knownmutation or polymorphism in standard databases
(dbSNP138 (http://www.ncbi.nlm.nih.gov/SNP/); 1000 genomes
(release October 2013, http://browser.1000genomes.org.); Exome
Variant Server (HLBI-EPS6500, http://evs.gs.washington.edu/EVS/
database accessed Sept, 2014). The novel GCH1 variant was iden-
tiﬁed in ﬁve of the affected members of the family, but not in
subject II:3 or unaffected subjects II:2 and III:4,5,7,9,13, nor in 300
UK control chromosomes. MLPA did not reveal any copy number
variation in SNCA, Parkin, PINK1, DJ-1 and LRRK2 or GCH1.
4. Discussion
We have identiﬁed a novel heterozygous missense variant
within GCH1 (c.5A > G) in ﬁve family members affected by PD or
DRD. Several arguments support the contention that this variant is
pathogenic. The variant cosegregates with disease state in the
family; it is absent from 300 UK control chromosomes tested here,
and from all the large public databases; furthermore, it is almost
completely conserved among species (Supplementary Fig. 2), and it
is predicted to replace one of the larger hydrophilic amino acids
with a small hydrophobic glycine within the N-terminal region of
the protein. It is well known that in-silico prediction tools possess
limited accuracy [6]. This mutation is predicted as pathogenic by
SIFT and SNP&GO, but not by PolyPhen-2 and Mutation Taster. The
clinical symptoms and signs observed in subjects II:1 and II:4 met
diagnostic criteria for PD. In both cases the diseasewasmore slowly
progressive than is usual in idiopathic PD. Subject II:3 had an iso-
lated rest tremor and subjects II:5, III:1 and III:11 were diagnosedl evaluation and blood sampling of the twelve family members studied.
Table 1
Summary of the clinical, functional neuro-imaging and molecular genetic data on subjects from the study family. PD denotes Parkinson's disease; DRD Dopa responsive
dystonia; N/A not done or not appropriate; MMSE mini mental state examination score; UPSIT University of Pennsylvania Smell Identiﬁcation Test; DaTSCAN dopamine
transporter imaging; Mod. moderate. Age and sex corrected percentile values for UPSIT scores are presented in brackets.
Subject &
gender
Age at eval. Age at sympt.
onset
Clinical
diagnosis
L-dopa
response
H&Y stage MMSE UPSIT score
(percentile)
DaT scan GCH1
mut. p.E2G
II:1 M 82 58 PD Y 3 27 21 (40th)
Severe microsmia
A Y
II:2 M 80 N/A Unaffected N/A N/A 27 31 (71st)
Mild microsmia
N N
II:3 M 78 75 Isolated rest
tremor
No Rx 1 30 21 (23rd)
Severe microsmia
1 A
2 N
N
II:4 M 68 50 PD Y 2 29 28 (31st)
Mod. microsmia
1 A
2 A
Y
II:5 M 66 44 DRD Y N/A 28 26 (24th)
Mod. microsmia
N Y
III:1 F 56 17 DRD Y N/A 30 35 (38th)
Normosomia
N Y
III:11 F 26 6 DRD Y N/A 29 37 (40th)
Normosmia
N Y
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young age and in the case of subject III:11 were more severe than
those seen in subject II:5, illustrating the extreme phenotypic
heterogeneity in this kindred and possibly reﬂecting the increased
penetrance of GCH1 mutations in females.
DaTSCAN data supported the clinical diagnoses in most cases.
The clinical phenotypes of DRD and PD and correspondingly
normal and abnormal scans were found in subjects carrying the
same GCH1 mutation. DAT imaging is typically normal in DRD.
Indeed DAT imaging has been proposed as a diagnostic tool to help
differentiate between DRD and early onset PD [5]. There have been
case reports of individuals with adult onset dystonia-parkinsonism
[7] or PDwithout any dystonia [8] carrying a GCH1mutation and an
abnormal DaTSCAN.
Recently, Mencacci and colleagues reported 4 unrelated in-
dividuals with adult onset parkinsonism, presumed pathogenic
GCH1 mutations and abnormal DaTSCANs [9].
These cases, and the two in our family (subjects III:1 and III:4),
raise the question as to whether PD, in patients with presumed
pathogenic GCH1 mutations, is in fact a rare phenotype of DRD.
Certainly the phenotype of DRD is suggested to be broad, as illus-
trated by a recently reported family with classical DRD, adult onset
PD and an MSA-like phenotype associated with a GCH1 two exon
deletion [3]. As recently speculated byMencacci and colleagues [9],
chronic dopamine deﬁciency resulting from GCH1 deﬁciency could
directly predispose to nigral cell death (rather than classical lewy
body associated neurodegeneration as typically seen in PD).
Although earlier studies screening for a GCH1 mutations in PD co-
horts did not identify a signiﬁcant role for genetic variation in GCH1,
recent studies have implicated GCH1 as a risk locus for PD [9,10].
An alternative, but less plausible, explanation in our family is the
coincident occurrence of two separate movement disorders: a
GCH1 mutation causing DRD in some individuals an additional
mutation (ie an unidentiﬁed mutation in an as yet unidentiﬁed PD
gene) causing PD coincidentally in others. In those with a GCH1
mutation and PD but no dystonia the lack of DRD phenotype could
then be explained by incomplete penetrance of the GCH1mutation.
Olfactory dysfunction is found in 70e100% of PD patients. As
DRD is a result of dopamine deﬁciency without neuronal cell death,
we would predict that UPSIT-40 data in DRD should be normal. In
our study, the mean UPSIT-40 score for affected subjects with the
GCH1mutationwas 29.4, compared to a previous study of olfaction
in PD, in which the mean score in 18 subjects with idiopathic PD
was 17.1, with a score of 27.6 in 27 age-matched controls [11]. The
small sample sizes which result from separating our individualswith the GCH1mutation limit any conclusions but the 2 individuals
with PD had a mean score of 24.5 versus the 3 with DRD who had a
mean score 32.7.
The DaTSCAN data for subject III:3, who had an isolated rest
tremor, is difﬁcult to explain. His ﬁrst scan was abnormal, but the
second scan performed 18 months later was normal. One expla-
nation is that he suffered a vascular embolic event occurring around
the time of the ﬁrst scan. An alternative explanation is that there
was a technical problem with one of the scans. There is also a
category of subjects with parkinsonism who have normal DaTS-
CANs, so called SWEDDs (Scans Without Evidence of Dopaminergic
Deﬁcit), with 11e15% of subjects with PD being found to have
normal nigrostriatal uptake of presynaptic ligands [12]. The novel
GCH1 mutation is not carried by subject III:3 and the most likely
explanation for his symptoms is that he has isolated rest tremor
due to an unrelated mechanism.
In further studies we will screen for GCH1 variants in subjects
with familial PD, and in subjects with parkinsonism who have
normal DAT scans, as well as pursuing further studies into the
functional effects of the novel variant described here. We anticipate
that future post-mortem histological data on affected individuals,
particularly those with the PD phenotype will shed more light on
disease mechanisms in this interesting family.
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